How to Help Your Patients Save Money on Voydeya: A Provider's Guide to Savings Programs

For PNH patients prescribed Voydeya (danicopan), cost is one of the most significant real-world access barriers. At $50,000–$100,000 per year for danicopan alone — on top of C5 inhibitor therapy — the financial burden is substantial even for insured patients. As the prescribing provider, your proactive involvement in connecting patients with savings programs and appealing coverage denials is often the decisive factor in whether a patient can afford to stay on therapy. This guide covers every financial assistance option available in 2026.

Understanding the Voydeya Cost Landscape

The average annual cost of Voydeya (danicopan) therapy is estimated at $75,000–$100,000 per patient per year. When added to a C5 inhibitor regimen, the total combination cost per patient per year can range from approximately $550,000 to $720,000 — making this one of the most expensive combination therapies in rare hematology. This cost reality means that nearly every patient will require financial assistance, and your office will play a central role in securing it.

Program 1: Alexion OneSource Copay Program — Primary Tool for Commercially Insured Patients

The Alexion OneSource Copay Program is the most powerful savings tool for patients with commercial health insurance. Key facts:

Maximum annual savings: Up to $15,000 per calendar year per patient

Potential out-of-pocket: As low as $0 per prescription for eligible patients

Eligibility: Commercially insured patients ONLY — does NOT apply to Medicare, Medicaid, TRICARE, or other federal programs

Enrollment: Submit the Prescriber and Patient Enrollment Form to OneSource (the same form used for REMS enrollment); fax to 1-800-420-5150 or call 1-888-765-4747

Provider action: Enroll patients in OneSource at the same time as the PA submission — do not wait until after PA approval

Program 2: Alexion Patient Assistance Program — For Uninsured or Underinsured Patients

For patients who are uninsured, underinsured, or whose insurance has denied coverage and appeals have been exhausted, Alexion offers a Patient Assistance Program (PAP). This program may provide Voydeya at no cost to qualifying patients who meet income eligibility criteria. The specifics of eligibility requirements and income thresholds are determined by Alexion — refer patients to OneSource (1-888-765-4747) to discuss their individual situation.

Program 3: Medicare and Medicaid — Government Payers Require Different Strategies

Patients on Medicare or Medicaid are federally prohibited from using manufacturer copay assistance programs. Voydeya falls under Medicare Part D (pharmacy benefit) as an oral self-administered drug. For these patients, consider:

Medicare Low Income Subsidy (Extra Help): Patients with limited income may qualify for Medicare's Extra Help program, which significantly reduces Part D costs. Refer eligible patients to Medicare.gov or 1-800-MEDICARE.

Independent charitable foundations: Unlike manufacturer programs, independent foundations CAN accept Medicare and Medicaid patients. See Program 4 below.

Medicaid coverage: For Medicaid patients, Voydeya coverage varies by state. Prior authorization is required. Submit strong medical necessity documentation including lab values showing EVH criteria.

Program 4: Independent Charitable Foundations

Independent disease foundations can assist with copays, insurance premiums, and related medical costs, regardless of insurance type (including Medicare and Medicaid):

HealthWell Foundation (healthwellfoundation.org) — has disease-specific funds for rare hematologic conditions; check their fund availability as these open and close periodically

Patient Advocate Foundation (patientadvocate.org) — copay relief and case management services for patients with chronic/life-threatening conditions

AA&MDS International Foundation (aamds.org) — PNH-specific patient support organization with financial assistance resources

NeedyMeds.org — free database of assistance programs by drug name and diagnosis

Provider Role: Fighting Denials to Reduce Patient Cost

One of the most effective ways to reduce patient cost is to prevent or overturn a PA denial — because a denied claim means full out-of-pocket cost (or no access at all). For Voydeya:

Submit complete, thorough PA documentation the first time — the most common denial reason is incomplete submission

On denial: immediately request peer-to-peer review — come prepared with ALPHA trial data (Lancet Haematol 2023), FDA prescribing information, and patient-specific lab trends

External appeals succeed 50–70%+ of the time for rare disease drugs — file external appeals for any patient with an urgent clinical need

Use Alexion's Field Reimbursement Managers (FRMs) through Access Navigator — they specialize in Voydeya payer negotiations

Creating a Coordinated Access and Savings Plan at Appointment

The most effective approach is to launch financial assistance enrollment at the same appointment where you decide to prescribe Voydeya:

Submit the REMS enrollment + OneSource enrollment form simultaneously

Submit the prior authorization the same day — don't wait for REMS confirmation

Identify the patient's insurance type (commercial vs. government) to select the correct savings pathway

For government insurance patients, immediately refer to independent foundations

Set expectations with patients: the first prescription may take 2–6 weeks; financial assistance is typically active before first fill

For more specialty drug access support, visit medfinder for providers. To share with your patients, our patient-facing savings guide can be found at How to Save Money on Voydeya in 2026.